BTIG analyst Julian Harrison has maintained their bullish stance on LQDA stock, giving a Buy rating on May 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison’s rating is based on the promising data from the ASCENT study, which highlights Yutrepia’s potential as a leading treatment for PH-ILD. The study showed that Yutrepia has a superior therapeutic window compared to existing treatments, with patients achieving higher doses and significant improvements in their 6-minute walk distance (6MWD). This suggests that Yutrepia could see strong adoption following its anticipated launch in mid-2025.
Additionally, a case study from the INSPIRE study demonstrated the benefits of switching patients from Tyvaso to Yutrepia, with notable improvements in patient condition and 6MWD. The upcoming PDUFA date in May 2025 for both PAH and PH-ILD indications further supports the potential for Yutrepia to capture a significant market share. These factors collectively underpin Harrison’s confidence in recommending a Buy rating for Liquidia Technologies.
In another report released on May 13, Scotiabank also maintained a Buy rating on the stock with a $36.00 price target.